Business
Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2025 Annual Meeting
BOULDER, Colo., Aug. 25, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company
About this update from Enliven Therapeutics, Inc.
[{"type":"text","content":"BOULDER, Colo., Aug. 25, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced the Company will present data from its ENABLE Phase 1a/1b clinical trial of ELVN-001 in both an oral and a poster presentation at the Society of Hematologic Oncology (SOHO) 2025 Annual Meeting, taking place September 3-6, 2025, at the George R. Brown Convention Center in Houston, Texas. This is an encore presentation of data that were previously presented at the European Hematology Association (EHA) 2025 Congress.\nDetails of the presentation are as follows:Title: ENABLE: A Phase 1a/1b Study of ELVN-001, a Selective Active Site Inhibitor of BCR::ABL1, in Patients With Previously Treated Chronic Myeloid LeukemiaPresenter: Michael J. Mauro, M.D.Poster Session Date/Time: Wednesday, September 3, 6:25 p.m. CDTPoster Location: Hall B3, Level 3Poster Number: CML-575Oral Session Title: Session V: Chronic Myeloid LeukemiaOral Session Date/Time: Thursday, September 4, 11:40 – 11:50 a.m. CDT\nFollowing the presentation, a copy will be available on the \"Program Presentations & Publications\" section of the Company's website at https://www.enliventherapeutics.com.\nAbout Enliven Therapeutics Enliven is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics to help people not only live longer, but live better. Enliven aims to address existing and emerging unmet needs with a precision oncology approach that improves survival and enhances overall well-being. Enliven's discovery process combines deep insights in clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies. Enliven is based in Boulder, Colorado. \nForward-Looking StatementsThis press release contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended) concerning Enliven and other matters that involve substantial risks and uncertainties. These statements may discuss goals, intentions and potential of our small molecule therapeutics. Forward-looking statements generally include sta...